根治性治疗后III期非小细胞肺癌预防性颅脑照射与观察的随机III期研究
NVALT-11/DLCRG-02研究纳入175例根治性治疗的III期NSCLC患者,随机接受预防性颅脑照射(PCI)或观察。总生存无显著差异,生活质量仅在PCI后3个月下降,此后与观察组相似。
要点
- PCI增加1-2级记忆障碍和认知障碍,但总生存无显著差异。
核心结论
- PCI显著降低III期NSCLC根治性治疗后症状性脑转移比例,但增加低级别毒性。
- 总生存无显著差异,生活质量仅PCI后3个月下降,之后与观察组相似。
研究设计与样本
- 随机III期研究,2009至2015年纳入175例III期NSCLC患者,PCI组87例,观察组88例。
- 患者在接受同步/序贯放化疗±手术后随机分组,主要终点为24个月症状性脑转移。
主要发现
- 中位随访48.5个月(95%CI 39-54个月),两组总生存无显著差异。
- 1-2级记忆障碍在PCI组26/86例 vs 观察组7/88例,认知障碍16/86例 vs 3/88例,均显著增加。
- 生活质量仅在PCI后3个月下降,此后与观察组相似。
关键数值与推荐
- 症状性脑转移定义为颅内压增高、头痛、恶心呕吐、认知或情感障碍、癫痫或局灶神经症状,并经MRI或CT证实。
- 主要终点为24个月症状性脑转移发生率。
临床怎么用
- 对于根治性治疗的III期NSCLC患者,PCI可考虑用于降低症状性脑转移风险,但需权衡低级别神经认知毒性。
- 治疗决策应个体化,结合患者对脑转移风险的担忧与认知功能影响。
局限性
- 样本量较小(175例),可能影响统计效能。
- 未报告无症状脑转移的监测数据。
- 长期认知功能影响需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging-were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy with or without surgery. The primary end point-development of symptomatic brain metastases at 24 months-was defined as one or a combination of key symptoms that suggest brain metastases-signs of increased intracranial pressure, headache, nausea and vomiting, cognitive or affective disturbances, seizures, and focal neurologic symptoms-and magnetic resonance imaging or computed tomography demonstrating the existence of brain metastasis. Adverse effects, survival, quality of life, quality-adjusted survival, and health care costs were secondary end points. Results Between 2009 and 2015, 175 patients were randomly assigned: 87 received PCI and 88 underwent observation only. Median follow-up was 48.5 months (95% CI, 39 to 54 months). Six (7.0%) of 86 patients in the PCI group and 24 (27.2%) of 88 patients in the control group had symptomatic brain metastases ( P = .001). PCI significantly increased the time to develop symptomatic brain metastases (hazard ratio, 0.23; [95% CI, 0.09 to 0.56]; P = .0012). Median time to develop brain metastases was not reached in either arm. Overall survival was not significantly different between both arms. Grade 1 and 2 memory impairment (26 of 86 v seven of 88 patients) and cognitive disturbance (16 of 86 v three of 88 patients) were significantly increased in the PCI arm. Quality of life was only decreased 3 months post-PCI and was similar to the observation arm thereafter. Conclusion PCI significantly decreased the proportion of patients who developed symptomatic brain metastases with an increase of low-grade toxicity.
引用
- De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. J Clin Oncol. 2018. PMID: 29787357. doi:10.1200/JCO.2017.77.5817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。